Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 9, Issue 6, Pages 789-797Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/17512433.2016.1179574
Keywords
Psoriasis; calcipotriene; betamethasone dipropionate; topical
Categories
Funding
- Galderma Laboratories
- Galderma
- Janssen
- Abbott Labs
- Amgen
- Stiefel/GlaxoSmithKline
- Celgene
- Anacor
- Janssen Pharmaceuticals LLC
Ask authors/readers for more resources
Introduction: Psoriasis affects an estimated 2% of the world's population, with higher rates in developed countries. 80% have mild-to-moderate disease and 50 to 80% have scalp involvement. Topical treatments are the mainstay of treatment.Areas covered: Two-compound calcipotriene and betamethasone dipropionate (BD) is a common topical combination therapy consisting of a vitamin D analogue and a corticosteroid. It comes in ointment, gel/suspension, and foam formulations. Phase II and III clinical trials have consistently shown the two-compound formulation to be effective and safe, with no clinically significant skin atrophy, calcium level changes, or adrenal suppression were seen. Topical scalp solution was also safe and effective in treating scalp psoriasis in pediatric populations.Expert commentary: Calcipotriene plus BD is more effective and safer than the individual ingredients in the same vehicle for treating body and scalp psoriasis. It should be considered a first line therapy for mild-to-moderate plaque psoriasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available